Results 241 to 250 of about 28,778 (289)

Antimicrobial Resistance in Enterobacterales Recovered from Urinary Tract Infections in France

Pathogens, 2022
International audienceIn the context of increasing antimicrobial resistance in Enterobacterales, the management of these UTIs has become challenging.
Eric Farfour, Laurent Dortet, Thomas Guillard   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales

Microbial Drug Resistance, 2022
The objective of this study was to identify putative mechanisms contributing to baseline cefiderocol resistance among carbapenem-resistant Enterobacterales (CRE). We evaluated 56 clinical CRE isolates with no previous exposure to cefiderocol.
Patricia J. Simner, Stephan Beisken, Yehudit Bergman, Michael Ante, Andreas E. Posch, Pranita D. Tamma   +5 more
openaire   +2 more sources

Rapidly spreading Enterobacterales with OXA-48-like carbapenemases

Journal of Clinical Microbiology
Enterobacterales (mostly Klebsiella pneumoniae, Escherichia coli) with OXA-48-like carbapenemases (e.g., OXA-48, -181, -232, -244) are undermining the global efficiency of carbapenem therapy. In the Middle East, North Africa, and some European countries,
G. Peirano, J. Pitout
semanticscholar   +1 more source

World Health Organization priority antimicrobial resistance in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus and Enterococcus faecium healthcare-associated bloodstream infections in Brazil (ASCENSION): a prospective, multicentre, observational study

The Lancet Regional Health - Americas
Summary Background Carbapenem-resistant Enterobacterales (CRE), Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE) are listed by World ...
L. Antochevis, C. M. Wilhelm, Beatriz Arns, D. Sganzerla, L. O. Sudbrack, Thais C.R.L. Nogueira, R. D. Guzman, A. S. Martins, Dan Cappa, A. C. dos Santos, J. Pascual, Vitor Hugo Perugini, E. Vespero, M. H. Rigatto, D. C. Pereira, Larissa Lutz, R. Leão, Elizabeth A. Marques, D. M. Henrique, A. A. Coelho, L. L. Frutuoso, Erika E. de A Sousa, Luiz F. Abreu Guimarães, Adriana Lúcia Pires Ferreira, A. C. Castiñeiras, M. Alves, João Paulo Telles, C. Yamada, Francieli P. de Almeida, E. Girão, Paulo C.P. de Sousa, Antonio G.N.D. de Melo, E. T. Mendes, V. D. F. Rocha, E. D. S. Neves, Marcello T. Ribeiro, C. E. F. Starling, M. S. Oliveira, Jorge L. M. Sampaio, A. F. Martins, A. Barth, A. Zavascki, Jéssica Nesello dos Santos, C. F. Ferreira, T. Vieceli, Julival Ribeiro Fagundes, R. Matias, Shisue Karina Katagiri, Olavo Neto, Rafaela Kuczynski da Rocha, C. Carrilho, M.E. Mauro de Almeida, H. Rosa, Valéria Paes Lima, Tazio Vanni, S. Nouér, Elizabeth Mendes Alves, J. Rodrigues, André Jhonathan Dantas, Gyselle de Souza Rebouças, J. de Oliveira   +60 more
semanticscholar   +1 more source

Trends in Enterobacterales Bloodstream Infections in Children

Pediatrics
OBJECTIVES Enterobacterales bloodstream infections (E-BSI) cause a significant burden of disease in children and are associated with antimicrobial resistance. We assessed temporal changes in the population-based incidence of E-BSI in children in Queensland, Australia.
Gibbs, Anna A.M., Laupland, Kevin B., Edwards, Felicity, Ling, Weiping, Channon-Wells, Samuel, Harley, David, Falster, Kathleen, Paterson, David L., Harris, Patrick N.A., Irwin, Adam D.   +9 more
openaire   +5 more sources

Aztreonam-avibactam Demonstrates Potent Activity Against Carbapenem-resistant Enterobacterales Collected From US Medical Centers Over a 6-year Period (2017–2022)

Open Forum Infectious Diseases
Background Carbapenem-resistant Enterobacterales (CREs) are a major public health threat because treatment options are limited. The predominant resistance mechanism in CREs is the production of carbapenemases.
K. Papp-Wallace, H. Sader, Joshua M. Maher, J. Kimbrough, M. Castanheira   +4 more
semanticscholar   +1 more source

Carbapenem-resistant Enterobacterales bloodstream infections related to death in two Brazilian tertiary hospitals

BMC Infectious Diseases
Bloodstream infection (BSI) caused by carbapenem-resistant Enterobacterales (CRE) is a major global public health concern due to its high lethality and limited treatment options.
Lorena Galvão de Araújo, Kehvyn Cedeño, A. P. Bomfim, Márcio de Oliveira Silva, Ana Verena Almeida Mendes, M. Barberino, E. Gouveia, F. Bahia, M. D. dos Reis, J. N. Reis   +9 more
semanticscholar   +1 more source

Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019–2023)

Journal of Antimicrobial Chemotherapy
Objectives To evaluate the in vitro activity of aztreonam/avibactam against Enterobacterales from European medical centres during the 5-year period prior to its approval for clinical use in Europe.
H. Sader, J. Kimbrough, Marisa L. Winkler, M. Castanheira, R. Mendes   +4 more
semanticscholar   +1 more source

Rapid ResaCeftazidime-Avibactam Enterobacterales NP Test: Rapid Detection of Ceftazidime-Avibactam Susceptibility in Enterobacterales

Journal of Clinical Microbiology, 2022
Ceftazidime-avibactam (CZA), a novel β-lactam/β-lactamase inhibitor combination, has good antibacterial activity against carbapenem-resistant Enterobacterales (CRE) producing class A and C and some class D carbapenemases, but in recent years, the emergence of CZA-resistant Enterobacterales ...
Luozhu Feng, Yining Zhao, Zhuocheng Yao, Xiaodong Zhang, Shufang Zheng, Lijiang Chen, Ying Zhang, Lingbo Wang, Tieli Zhou, Jianming Cao   +9 more
openaire   +2 more sources

Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Türkiye: A multi-centre retrospective matched-cohort study.

International Journal of Antimicrobial Agents
BACKGROUND Due to underrepresentation of carbapenemase-producing Enterobacterales infections in randomized controlled trials with ceftazidime-avibactam (CZA) and high cost of CZA therapy, other appropriate antimicrobial therapies (OAAT) are still being ...
A. T. Aslan, E. Tanrıverdi, S. Kaya, Gözde Dalgan, N. Saltoğlu, Ezgi Yılmaz, Yeliz Çiçek, Mesut Yılmaz, Ç. Erol, Ö. Azap, G. Hazırolan, Osman Dağ, Zeynep Türe Yüce, Pınar Sağıroğlu, Damla Boztaş, Muhammed Cihan Işık, B. Otlu, Patrick N A Harris, David L Paterson, M. Akova   +19 more
semanticscholar   +1 more source